|Bid||0.9200 x 1100|
|Ask||0.9201 x 100|
|Day's Range||0.9000 - 0.9629|
|52 Week Range||0.8200 - 3.3500|
|PE Ratio (TTM)||-2.75|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - July 27, 2017) - Trading resumes in: Company: Intellipharmaceutics International Inc. TSX Symbol: IPCI (All issues) ...
A panel of independent advisers to the U.S. Food and Drug Administration concluded on Wednesday that there is not enough evidence to support the approval of Intellipharmaceutics International Inc's long-acting opioid painkiller. Toronto-based Intellipharma's painkiller has been developed as a unique abuse-deterrent version of Purdue Pharma's oft-abused blockbuster OxyContin, which already has tamper-resistant properties. In a preliminary review on Monday, FDA scientists raised concerns that Intellipharma had not provided adequate data on the abuse potential of the drug as part of its U.S. marketing application.
U.S. Food and Drug Administration scientists on Monday raised concerns that Intellipharmaceutics International Inc failed to provide data from studies testing the abuse potential of its long-acting opioid painkiller. Canada-based Intellipharma's product, Rexista, has been developed as a unique abuse-deterrent version of Purdue Pharma's OxyContin, which already has tamper-resistance properties. In a preliminary review posted ahead of a meeting of independent advisers on Wednesday, FDA scientists said that abuse-liability data had not been submitted as part of Rexista's marketing application.